Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Despite the first reports concerning benzodiazepine dependence being published in the early 1960s literature, the risk of benzodiazepine addiction is still greatly debated. The severe discomfort and life threatening complications usually experienced by long-term benzodiazepine users who suddenly interrupt benzodiazepine intake have led to the development of several detoxification protocols. A successful strategy used by our Addiction Unit is abrupt benzodiazepine cessation by administering flumazenil slow subcutaneous infusion (FLU-SSI) with an elastomeric pump. Although some studies proved the efficacy of flumazenil infusion more than 20 years ago, only a few centres in the world offer this method to their patients. This paper reports the data related to 214 subjects addicted to high doses of benzodiazepine and treated with the FLU-SSI method between 2012 and 2014. This technique is less invasive and requires less nursing intervention than intravenous infusion. Our data support FLU-SSI as a possible efficient strategy for the treatment of patients with long-term, high-dose benzodiazepine addiction, and could become a routine therapy as long as the necessary further studies on dose, duration of infusion and safety issues are carried out.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 2×
“However, the use of benzodiazepines may lead to abuse, tolerance and dependence on therapeutic doses as well as on high doses; the latter with a complete loss of control (Ashton, 2005; Lader, 2011; Nutt et al., 2010).”
BackgroundBenzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
Withdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318 · cited 1×
“, 1996, 2002; Lader and Morton, 1992), and now its use is supported by several experts (Lader, 2011; Lader et al., 2009).”
BackgroundOhayon, M. M., & Lader, M. H. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0912 · Cited by 271
Benzodiazepines: Risks and Benefits. A Reconsideration
Baldwin, D. S., Aitchison, K., Bateson, A., Curran, H. V., Davies, S., Leonard, B., Nutt, D. J., Stephens, D. N., & Wilson, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113503509 · Cited by 249 · cited 1×
“In case of long-term use, the risk of harmful effects and dependence should therefore be taken into consideration and the benefits of an alternative short or intermittent treatment should be assessed (Baldwin et al., 2013).”
BackgroundBenzodiazepine dependence and its treatment with low dose flumazenil
Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., & Hulse, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12023 · Cited by 165
Petitjean, S., Ladewig, D., Meier, C. R., Amrein, R., & Wiesbeck, G. A. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328105e0f2 · Cited by 132 · cited 2×
“A cross-sectional study, performed on 520,000 patients in Switzerland (Petitjean et al., 2007), showed that approximately 6.6% of the Swiss adult population misused benzodiazepines, and about 1.6% had an intake even higher than twice the recommended daily dose.”
BackgroundInfluentialGerra, G., Zaimovic, A., Giusti, F., Moi, G., & Brewer, C. (2002) · Addiction Biology · doi:10.1080/1355621021000005973 · Cited by 82
Cited by
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
MacDonald, T., Gallo, A. T., Basso-Hulse, G., Bennett, K. S., & Hulse, G. K. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109501 · Cited by 12
Further evidence on the interplay between benzodiazepine and Z-drug abuse and emotion dysregulation
Colizzi, M., Meneghin, N., Bertoldi, A., & Lugoboni, F. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100234 · Cited by 9
Self-citationBenzodiazepine Withdrawal: Clinical Aspects
Wright, S. L. (2020) · The Benzodiazepines Crisis · doi:10.1093/med/9780197517277.003.0008 · Cited by 7
Metadata
- Authors
- Faccini, M., Leone, R., Opri, S., Casari, R., Resentera, C., Morbioli, L., Conforti, A., & Lugoboni, F.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-07-10
- Volume
- 30
- Issue
- 10
- Pages
- 1047-1053
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2411201481
- Cited by
- 38
- References
- 13
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases. https://app.cochat.ai/papers/10.1177/0269881116647505
- The paper
- Faccini, M., Leone, R., Opri, S., Casari, R., Resentera, C., Morbioli, L., Conforti, A., & Lugoboni, F. (2016). Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116647505
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.